Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Year: 2023
Type: supplementary-materials
Abstract: Evaluation of circulating MDSC. (A) Changes in total MDSC and (B) monocytic (M-MDSC) and granulocytic (G-MDSC) subsets at cycle 1, day 15 (C1D15) compared to screening in the entire patient cohort. (C) Levels of circulating MDSC at screening by clinical response and changes during study treatment compared to screening in partial response (PR, orange) and stable disease (SD, green) patients. Each symbol represents one patient (n = 9). Line indicates mean.
Authors: Dwight H. Owen, Brooke Benner, Lai Wei, Vineeth Sukrithan, Ashima Goyal, Ye Zhou, Carly Pilcher, Sheryl-Ann Suffren, Gwen Christenson, Nancy Curtis, Megan Jukich, Emily Schwarz, Himanshu Savardekar, Ruthann Norman, Sarah Ferguson, Barbara Kleiber, Robert Wesolowski, William E. Carson, Gregory A. Otterson, Claire F. Verschraegen, Manisha H. Shah, Bhavana Konda
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361955672